drugset
Drugs / PF-06410293
last change Aug 2023 re-read 2 minutes ago

PF-06410293

also known as adalimumab-afzb · Abrilada · ADL-PF · Amsparity · Xilbrilada

Protein / enzyme biologic

Developed for
rheumatoid arthritis
Investigated by
Pfizer

Trials 4 · a red edge is where a trial was stopped

today NCT04230213 · Ph 3 NCT02480153 · Ph 3 NCT02237729 · Ph 1 NCT01870986 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02237729 Sep 2014 → Mar 2015 — Pfizer Completed No outcome recorded
Phase 1 NCT01870986 May 2013 → Feb 2014 — Pfizer Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04230213 Jan 2020 → Jun 2021 rheumatoid arthritis Pfizer Completed No outcome recorded
Phase 3 NCT02480153 Jun 2015 → Aug 2016 rheumatoid arthritis Pfizer Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2019-11-18 Pfizer FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions pfizer.com ↗
2017-01-05 Pfizer Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) pfizer.com ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as PF-06410293 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237729 ↗
3

NCT04230213 ↗

NCT01870986 ↗

NCT02480153 ↗
Known as Abrilada “adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022
Known as adalimumab-afzb “adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022
1

“adalimumab biosimilar PF-06410293 (adalimumab-afzb)” PMID 38251497 ↗ Aug 2023
Known as ADL-PF “adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022
Known as Amsparity “adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022
Known as Xilbrilada “adalimumab (ADL) biosimilar PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada®/Amsparity®/Xilbrilada®)” PMID 35304684 ↗ Mar 2022
Modality Protein / enzyme biologic “Biological: PF-06410293” NCT02480153 ↗
Route Subcutaneous “administered by sub-cutaneous injection” NCT01870986 ↗